The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
Abstract
PURPOSE: To study the impact of Procrit (epoetin alfa; Amgen Inc, Thousand Oaks, CA) on quality of life, transfusion requirements, and hemoglobin in anemic cancer patients receiving chemotherapy. PATIENTS AND METHODS: More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic chemotherapy in an open-label study. Patients were treated with epoetin alfa 150 U/kg three times weekly, which could be doubled if the therapuetic response was judged inadequate. Total treatment was up to 4 months. RESULTS: Of the 2,342 patients enrolled, data were available for 2,030 patients. Of the 2,030, 1,047 patients completed all 4 months of epoetin alfa therapy. Epoetin alfa was associated with significant increases in mean self-rated scores for energy level, activity level, and overall quality of life; these improvements correlated with the magnitude of the hemoglobin increase and were independent of tumor response. In addition, epoetin alfa was associated with a significant increase in mean hemoglobin and with a significant decrease in the proportion of patients requiring transfusions (baseline to final value, P < .001). Epoetin alfa was well tolerated. CONCLUSION: Epoetin alfa is effective in improving the functional status and quality of life in anemic cancer patients receiving chemotherapy, as well as increasing hemoglobin level and decreasing transfusion requirements. Improvement in functional status can be attributed to an increase in hemoglobin level, demonstrating that quality of life in this group of patients can be improved by aggressively treating anemia. Further studies will be required to define the optimal doses and schedules for epoetin alfa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graphic representation of pain
Scott, J., & Huskisson, E. C. (1976) · Pain · doi:10.1016/0304-3959(76)90113-5 · Cited by 2,706
Effect Sizes for Interpreting Changes in Health Status
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989) · Medical Care · doi:10.1097/00005650-198903001-00015 · Cited by 2,401
Clinical applications of visual analogue scales: a critical review
McCormack, H. M., de L. Horne, D. J., & Sheather, S. (1988) · Psychological Medicine · doi:10.1017/s0033291700009934 · Cited by 2,108
Interpretation of quality of life changes
Lydick, E., & Epstein, R. S. (1993) · Quality of Life Research · doi:10.1007/bf00435226 · Cited by 527
Sensitivity and accuracy of the visual analogue scale: a psycho‐ physical classroom experiment.
Maxwell, C. (1978) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1978.tb01676.x · Cited by 465
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.671 · Cited by 431
Vertical or horizontal visual analogue scales.
Scott, J., & Huskisson, E. C. (1979) · Annals of the Rheumatic Diseases · doi:10.1136/ard.38.6.560 · Cited by 427
HUSKISSON, E. C. (1982) · PubMed · Cited by 395
Beusterien, K. M., Nissenson, A. R., Port, F. K., Kelly, M., Steinwald, B., & Ware, J. E. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v75763 · Cited by 217
Prediction of response to erythropoietin treatment in chronic anemia of cancer [see comments]
Ludwig, H., Fritz, E., Leitgeb, C., Pecherstorfer, M., Samonigg, H., & Schuster, J. (1994) · Blood · doi:10.1182/blood.v84.4.1056.1056 · Cited by 196
Cascinu, S., Fedeli, A., Ferro, E. D., Fedeli, S. L., & Catalano, G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.1058 · Cited by 194
Assessment of the quality of life of patients with advanced cancer
Gough, I. R., Furnival, C. M., Schilder, L., & Grove, W. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90042-1 · Cited by 178
Henry, D. H., & Abels, R. I. (1994) · PubMed · Cited by 175
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
Platanias, L. C., Miller, C. B., Mick, R., Hart, R. D., Ozer, H., McEvilly, J. M., Jones, R. J., & Ratain, M. J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.11.2021 · Cited by 112
Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain
Rodríguez, M., Barutell, C., Rull, M., Gálvez, R., Pallarés, J., Vidal, F., Aliaga, L. A., Moreno, J. F., Puerta, J. L., & Ortiz, P. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90524-x · Cited by 65
Cited by
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
Groopman, J. E., & Itri, L. M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.19.1616 · Cited by 929
Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.06.019 · Cited by 925
King, C. H., Dickman, K., & Tisch, D. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66457-4 · Cited by 899
Metadata
- Authors
- Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S., & Vadhan-Raj, S.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-03
- Volume
- 15
- Issue
- 3
- Pages
- 1218-1234
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1821554592
- Cited by
- 693
- References
- 15
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.